Targeting CtBP1 expression using CRISPR-Cas9-mediated gene editing holds great promise as a novel therapeutic strategy for inhibiting the growth and progression of ESCC tumors and sensitizing cells to paclitaxel. The gene discussed is CTBP1; the disease is esophageal squamous cell carcinoma.